Get the Stockscreener App
34.16
1.52%
-0.375
Immunovant Inc stock is traded at $34.16, with a volume of 759.45K.
It is down -1.52% in the last 24 hours and down -21.48% over the past month.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
See More
Previous Close:
$34.54
Open:
$34.21
24h Volume:
759.45K
Relative Volume:
0.62
Market Cap:
$7.06B
Revenue:
-
Net Income/Loss:
$-505.61M
P/E Ratio:
-12.34
EPS:
-2.7697
Net Cash Flow:
$-407.32M
1W Performance:
-9.65%
1M Performance:
-21.48%
6M Performance:
+42.68%
1Y Performance:
+120.02%
1-Day Range:
$33.35
$34.55
1-Week Range:
$33.35
$38.35
52-Week Range:
$15.22
$45.42
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-410-3120
Address
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
34.16 | 7.13B | 0 | -505.61M | -407.32M | -2.7697 |
VRTX
Vertex Pharmaceuticals Inc
|
521.91 | 130.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
792.79 | 82.55B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
184.30 | 72.70B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
953.24 | 59.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
192.41 | 40.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-26 | Initiated | Bernstein | Mkt Perform |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-14-25 | Initiated | Truist | Hold |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Mar-03-25 | Initiated | Jefferies | Hold |
| Jan-03-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Lilly’s latest China drug deal; Immunovant’s setback in lupus - Yahoo Finance
Immunovant stock rating maintained at Buy by H.C. Wainwright - Investing.com Canada
Roivant reports top-line data from IMVT-1402 CLE trial - Yahoo Finance
H.C. Wainwright Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $41 - Moomoo
Immunovant stock falls 6.02 percent after lupus trial miss - AD HOC NEWS
Immunovant Scraps Lupus Skin Treatment After Midstage Trial Falls Short - finance.biggo.com
Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program - Barron's
Why is Immunovant stock sliding today? By Investing.com - Investing.com Canada
Immunovant drops cutaneous lupus program after IMVT‑1402 trial miss - Mugglehead Investment Magazine
Why Is Immunovant Stock Falling Wednesday?Roivant Sciences (NASDAQ:ROIV), Immunovant (NASDAQ:IMVT) - Benzinga
Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows - Yahoo Finance
Immunovant Shares Down 6.7% Premarket After C - Moomoo
Immunovant stock falls after lupus drug trial misses goal By Investing.com - Investing.com Canada
Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss - Yahoo Finance
Immunovant Shares Fall 6% After IMVT-1402 Lupus Study Misses Primary Endpoint - Yahoo Finance
Trial miss for Immunovant’s study of IMVT-1402 in CLE - The Pharma Letter
Immunovant halts lupus drug development after trial miss - Investing.com
Roivant slips on trial setback for Immunovant (ROIV:NASDAQ) - Seeking Alpha
Immunovant halts lupus drug development after trial miss By Investing.com - Investing.com Canada
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus - manilatimes.net
A skin-lupus drug study missed its main goal. Its developer plans to stop testing it. - Stock Titan
Immunovant stock edges lower after recent clinical pipeline focus - AD HOC NEWS
Behavioral Patterns of IMVT and Institutional Flows - Stock Traders Daily
Piper Sandler Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $66 - Moomoo
Immunovant Stock Gains 12.4% in a Month: What's Driving It? - easternprogress.com
Immunovant stock holds gains as investors eye upcoming data and recent revenue growth - AD HOC NEWS
Kuehn Law investigates Immunovant over potential fiduciary breaches - scanx.trade
Immunovant Q1FY27 Results: $950m Moderna settlement boosts cash - scanx.trade
Immunovant Q1 2027 Earnings Call: Complete Transcript - Benzinga
Immunovant (IMVT) Stock Looks Expensive Based On Its Book Value - Yahoo Finance
How (IMVT) Movements Inform Risk Allocation Models - Stock Traders Daily
Immunovant Announces Voting Outcomes from 2026 Annual Stockholders Meeting - Kalkine Media
Immunovant (IMVT) Slips 0.94% to $39.12 as Shares Test Resistance at $41.08OBV Breakout - vinanet.vn
Why (IMVT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Immunovant's Risk/Reward Profile Balanced After Recent Rally, UBS Says - marketscreener.com
Immunovant (IMVT) Watch: Stays Close to Unchanged at $44.37; Technical Setup: Support at $42.15 and Resistance at $46.59 Frame the Range at the CloseBear Flag - vinanet.vn
Deep Track Capital, LP Trims Immunovant Inc (IMVT) Stake in Stra - GuruFocus
Immunovant Inc GLP-1 Receptor Agonists Weight Management Diabetes Treatments *79wfgdDXy* - Villa de la Orotava
immunovant inc glp 1 receptor agonist diabetes weight managementView IiKNF3uia - Villa de la Orotava
Immunovant (IMVT) Results at a Glance: The Available Earnings Metric Delivers a Miss under the Current Snapshot; Post-Earnings: Shares Move Lower 1.98% in the Available RecordAnalyst Consensus Shift - vinanet.vn
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm - Morningstar
Immunovant Inc GLP-1 Receptor Agonists Weight Management Diabetes Treatments *BI2Y6DHdO* - scchr.jp
Investigation launched into Immunovant officers for possible self-dealing harming shareholders - Pluang
Immunovant (IMVT) Stock: Moves 1.49% Up to $44.96 in Latest Trading; Immediate View: Support at $42.71 and Resistance at $47.21 Frame the Range in the Latest ReadingPassive Flow - vinanet.vn
Immunovant (IMVT) Q1 2027 Earnings Call Transcript - AOL.com
Immunovant (IMVT) Holds Steady at $41.82: Consolidation Between Key Support and ResistanceThematic ETF Flow - vinanet.vn
GSA Capital Partners LLP Takes $2.52 Million Position in Immunovant, Inc. $IMVT - MarketBeat
Assenagon Asset Management S.A. Has $639,000 Holdings in Immunovant, Inc. $IMVT - MarketBeat
Immunovant (IMVT) Holds Steady at $41.82 as Shares Consolidate in a Tight RangeGamma Exposure - vinanet.vn
Dimensional Fund Advisors LP Sells 103,356 Shares of Immunovant, Inc. $IMVT - MarketBeat
Why Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype - simplywall.st
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunovant Inc Stock (IMVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pande Atul | Director |
Aug 28 '26 |
Sale |
43.27 |
1,500 |
64,905 |
116,731 |
| Gloria Melanie | Chief Operating Officer |
Aug 20 '26 |
Sale |
44.16 |
3,056 |
134,953 |
219,301 |
| Pande Atul | Director |
Jul 24 '26 |
Option Exercise |
8.43 |
1,500 |
12,645 |
118,231 |
| Pande Atul | Director |
Jul 24 '26 |
Sale |
39.80 |
1,500 |
59,700 |
116,731 |
| Girao Tiago | Chief Financial Officer |
Jul 23 '26 |
Sale |
38.69 |
6,798 |
263,015 |
240,798 |
| Stout Jay S | Chief Technology Officer |
Jul 23 '26 |
Sale |
38.69 |
2,857 |
110,537 |
205,341 |
| Gloria Melanie | Chief Operating Officer |
Jul 08 '26 |
Sale |
39.55 |
2,036 |
80,532 |
222,357 |
| Van Tuyl Christopher | Chief Legal Officer |
Jul 08 '26 |
Sale |
39.55 |
1,206 |
47,702 |
179,391 |
| Stout Jay S | Chief Technology Officer |
Jul 08 '26 |
Sale |
39.55 |
3,487 |
137,925 |
208,198 |
| Venker Eric | Chief Executive Officer |
Jul 01 '26 |
Option Exercise |
14.46 |
92,188 |
1,333,038 |
344,001 |
0.99%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):